Published in final edited form as:

Int Immunopharmacol. 2008 February ; 8(2): 161–165.

Assembly, Activation, and Physiologic Influence of the Plasma Kallikrein/Kinin System

Alvin H. Schmaier

Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH

Abstract

The plasma kallikrein/kinin system that consists of the proteins factor XII, prekallikrein, and high molecular weight kininogen was first recognized as a surface-activated coagulation system arising when blood or plasma interacts with artificial surfaces. Although surface-activated contact activation occurs in vivo when various negatively charged surfaces become exposed, including a developing platelet thrombus, a physiologic, non-injury mechanism for activation, regulation, and function of this system has been elusive. Recent investigations have shown that there is a physiologic pathway for assembly and activation of this system independent of factor XII. Gene deficient mice of the bradykinin B2 receptor and factor XII have been recognized to have reduced risk for arterial thrombosis. This plasma proteolytic system influences arterial thrombosis independent of influencing hemostasis. Thus, the plasma kallikrein/kinin system has two mechanisms for its activation: one that is dependent and another independent of factor XII. Better understanding of this system may lead to insight into mechanisms for arterial thrombosis, independent of hemostasis.

There have been several major advances in understanding on the plasma kallikrein/kinin system not completely addressed in recent reviews (1,2). These include 1) a proposal of a model for a multiprotein receptor complex that mediates assembly and activation of the zymogens of this system, 2) identification of a specific prekallikrein (PK) activator that provides a physiologic basis for the initiation of activation of factor XII (FXII) independent of autoactivation, and 3) several animal models have been established and their influence on thrombosis risk has been determined.

Intravascular Assembly of the Plasma Kallikrein/Kinin System

It was recognized that HK, FXII, and PK specifically, saturably, and reversibly bind to cultured endothelial cells, platelets, and granulocytes (3-8). Efforts have identified specific binding sites, putative receptors, for HK and FXII. HK serves as the major binding site for PK and FXI, although both proteins can bind to endothelial cells independent of HK (3,9). Several membrane proteins have also been recognized as HK binding proteins. These include gC1qR, urokinase plasminogen activator receptor (uPAR), and cytokeratin 1 (10-13). When HK is proteolyzed by plasma kallikrein or other proteases to form HKa, membrane tropomyosin also functions as a binding site, putative receptor, uniquely for this form of kininogen (14). FXII also has been shown to bind to gC1qR, uPAR, and CK1 (11,15). Heparan sulfate proteoglycans,

Address Correspondence to: Dr. Alvin H. Schmaier, Case Western Reserve University, University Hospital Case Medical Center, Division of Hematology and Oncology, 10900 Euclid Avenue WRB2-130, Cleveland, OH 44106-7284, 216-368-1172 (tel), 216-368-3014 (fax) schmaier@case.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

a negatively charged surface, has also been proposed as additional cell membrane sites for HK binding, although there is disagreement as to the degree it contributes to HK expression on cells (16-18). PK binds to HK on cell membranes; PK binding sites other than HK have not been identified to date even though it has been demonstrated to specifically bind to endothelial cells independent of HK (3,19). Factor XI also binds to HK on cell membranes, but unlike PK, also binds to prothrombin and the glycoprotein Ib α -IX-V complex on platelets as well (19-21). Since both PK and factor XI circulate in plasma almost completely bound to HK, PK binding to endothelial cells predominates over factor XI binding (19,22). The reasons for this finding are as follows: 1) the concentration of PK (450 nM) is more than 10-fold greater than that of factor XI (30 nM) in plasma and 2) the free Zn²⁺ concentration required for PK binding is only 0.3 μ M, while that for factor XI binding is 7 μ M (19). In order to have factor XI binding to cells in intravascular compartment or activated platelets, cellular disruption is necessary to provide a sufficiently high local zinc ion concentration in their releasate or lysates to support this interaction (19).

Activation of the Plasma Kallikrein/Kinin System

Although the above investigations indicate a mechanism for physiologic assembly on cultured endothelial cells, they do not indicate a pathway for activation of the system. Insight into an activation mechanism arose out of serendipity while performing investigations to examine the mechanism(s) by which single chain urokinase becomes activated by plasma kallikrein (23). When HK and PK were assembled on endothelial cells, plasma kallikrein activity arose independent of added FXIIa and was able to occur in the presence of neutralizing antibody to FXII and FXII-deficient plasma, but not PK-deficient plasma (3). These results were not expected since a mechanism for PK activation independent of activated FXII had not been previously identified. Similar results occurred when HK and PK were assembled on endothelial cell matrix (24). Formed plasma kallikrein results in kinetically favorable single chain urokinase activation in this system (3,25). Plasma kallikrein forms when HK and PK assemble on endothelial cells and results in kinetically favorable factor XII activation (26). These data present an alternative hypothesis for factor XII activation independent of autoactivation on a negatively charged artificial or biologic surface. The increased requirements for free Zn²⁺ for FXII binding to endothelial cells suggest that FXII's association and activation on endothelial cells follows HK and PK assembly and activation (15,19). Two recent animal knockouts suggest that this proposed mechanism for PK activation *in vivo* may occur constitutively. First, C1 INH knockout mice have constitutive vascular leakage that is blocked by a bradykinin B2 receptor (B2R) antagonist or by mating C1 INH and B2R knockout mice (27). Since plasma bradykinin only arises from plasma kallikrein formation, bradykinin must be constantly formed *in vivo* to give the constitutive paw edema seen in the C1 INH deletion mice (27). Bradykinin formation can only occur if plasma kallikrein is formed *in vivo*. Second, factor XII knockout mice still have formed bradykinin in their plasma indicating that at least one other mechanism for bradykinin formation exists in the intravascular compartment (28).

Proof that there is a PK activator on endothelial cells required that the activator be identified. After establishing an assay to measure the PK activator, the entity was purified from endothelial cell cultures (4). On amino acids sequencing, the isolated PK activator was identified to be the serine protease prolylcarboxypeptidase (PRCP) (4). PRCP was first recognized as a degrading enzyme for bradykinin and angiotensin II (29,30). This enzyme inactivates bradykinin and angiotensin II with a $K_i \approx 1$ and 0.15 mM, respectively, by cleaving Pro-X bonds on the carboxy-terminus of the protein (30,31). Interestingly, des-Arg⁹-bradykinin (RPPGFSPF) is not a substrate for PRCP indicating that it is not just a simple exopeptidase cleaving after Pro-X bonds (32). Both purified and recombinant PRCP activate PK with a $K_m \sim 9$ -17 nM making it an endoprotease (4,31). PRCP also was associated with endothelial cell matrix (32). Although originally purified from lysosomes, PRCP is a membrane protein since it is constitutively

expressed on endothelial cell membranes where it is functional and upon gene trap targeting it was interrupted along with other membrane proteins by homing with a CD4 membrane signal (3,31,33-35). More recent cell biology studies since PRCP was first described as a lysosomal protease suggest that lysosomal compartments in all eukaryotic cells are the endomembrane system that is intimately involved in the export of internal constituents (36). PRCP is a risk factor for metabolic syndrome in men and a PRCP polymorphism is associated with preeclampsia in women (37,38). Further confirmation that PRCP is a PK activator was performed by over expressing PRCP in CHO cells (39). CHO cells with over-expressed PRCP have increased PK activating activity over control; treatment of these cells with siRNA ameliorates the PK activation on these cells and control cells. Last, transfected CHO mostly express PRCP on their membrane. These combined studies indicate that there is a constitutive, physiologic mechanism for PK activation on endothelial cells in the intravascular compartment.

Thrombosis risk

There is emerging information that the plasma kallikrein/kinin system influences thrombosis risk. This influence on thrombosis risk is independent of any influence on hemostasis. Although patients with factor XII, prekallikrein, and high molecular weight kininogen deficiency do not have bleeding disorders, all of these deficiencies are exceedingly rare and characterization of the phenotypes of these individuals is not been possible due to the dispersed small patient population. FXII deficiency is most common. Clinical investigations for venous thrombosis risk or on polymorphisms of FXII and their influence on cardiovascular disease have been conflicting (see below). The clearest information on thrombosis risk or risk amelioration shown to date has been derived from mouse models of this system, in which unexpected findings demonstrate that drawing conclusions from *in vitro* data or observations on rare patients may be fraught with error. Two of these models will be reviewed below.

Bradykinin B2 Receptor Deletion Mice

Since bradykinin induces NO, prostacyclin, and tPA release from endothelial cells, we hypothesized that the B2R knockout mouse would be prothrombotic. To our surprise, B2R KO mice in a B6;129S7 background were protected from arterial thrombosis on a free radical carotid artery injury model (40). This result was unexpected and was not predicted from *in vitro* experiments. The mechanism for thrombosis protection is possibly twofold. First, in the absence of the B2R, the angiotensin receptor 2 is over-expressed. The B2R and angiotensin receptor 2 co-localize in cells (40,41). Second, there is also increased formed angiotensin II as result of reduced bradykinin metabolism and its increased angiotensin converting enzyme turnover (40). Reduced bradykinin metabolism results from less uptake by its receptor and intracellular degradation (42). The increased angiotensin II binds to the over-expressed endothelial cell angiotensin receptor 2 to increase NO and prostacyclin to prolong the bleeding time of these animal (40). Bradykinin 1-5 (RPPGF) also is elevated in these animals as result of reduced bradykinin uptake and degradation (40,42). Preliminary studies suggest that the elevated RPPGF levels seen in these animals also may contribute to the thrombosis protection seen, but this notion is not yet proven. These combined studies indicate that bradykinin and its receptor system indirectly influence thrombosis risk by its direct influence on endothelial cell biology and its cross-talk with the peptides and receptors of the plasma renin angiotensin system (40,43). Partially consistent with our findings, other investigators have showed that B2R KO mice in a C57BL6 background have smaller infarct volumes with less edema and longer survival whereas B2R KO mice in a B6,129S7 background do not (44,45). Difference in how the investigations were performed between the laboratories may account for the opposite results seen, but murine genetic background differences may contribute as well. In

our hands, B2R KO mice in a C57BL6 background are not protected from thrombosis (unpublished).

Factor XII Deletion mice

Although bradykinin and kininogen may contribute to the constitutive anticoagulant nature of the intravascular compartment, factor XII in epidemiological studies appears to have an opposite effect (46,47). A polymorphism in factor XII (46C/T) is associated with increased risk for thrombosis (48). This polymorphism is associated with reduced activated FXIIa and higher risk for coronary heart disease that is influenced by hypercholesterolemia (49-51). The mechanism by which this polymorphism is associated with arterial thrombosis is not completely known. Individuals homozygous for the 46C/T polymorphism have lowered factor XII levels. Further, they may have lowered levels of an activated form of FXII. The degree of free FXIIa levels and cardiovascular risk has been recognized (52,53). Reduced activated forms of FXII may be associated with reduced total fibrinolytic activity, although this mechanism is as of yet, unproven. These notions suggest that lowered FXII may be associated with increased thrombosis risk. This interpretation is opposite to what has been learned from examining thrombosis risk in FXII deficient mice (46,54,55). Factor XII deficient mice have reduced thrombus after induction of arterial clots (46,54). These data suggest that FXII contributes to the extent of thrombus formation *in vivo*; the absence of FXII results in reduced thrombus size (55). The mechanism for the increased size of thrombus in mice that have normal levels of FXII is not completely known but may be related to increased contact activation occurring on a developing thrombus. Polyphosphates secreted from activated platelets or intravascular RNA accelerates FXII-dependent coagulation reactions (56,57). Developing thrombus may form a surface that promotes FXII autoactivation, amplification of its activation with HK and PK, and increased factor XI activation leading to thrombin formation. If this mechanism proves to be correct, then a pathophysiologic pathway for *in vivo* contact activation occurs. Therapeutic inhibition of FXII could result in reduced thrombus formation without bleeding. These results were not predicted by *in vitro* investigations on the biochemistry and cell biology of FXII. Thus animal models provide new insight into the activity of this protein.

Summary

These combined investigations suggest that the plasma kallikrein/kinin system has varied physiologic activity. On a constitutive basis, its assembly in the intravascular compartment contributes to basal bradykinin formation by prekallikrein activation independent of factor XIIa which is important for the maintenance of vascular homeostasis. When vessel injury occurs and thrombus begins to form, secondary activation of factor XII through contact activation on the developing thrombus may be important for the size and strength of intravascular thrombus. Recognition of these two mechanisms for activation of the plasma kallikrein system allows for the beginning of understanding its varied physiologic activities.

Bibliography

1. Sainz IM, Pixley RA, Colman RA. Fifty years of research on the plasma kallikrein-kinin system: From protein structure and function to cell biology and in-vivo pathophysiology. *Thromb Haemost* 2007;98:77-83. [PubMed: 17597995]
2. Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease. *J Thromb Haemost* 2007;5:1106-1112. [PubMed: 17388803]
3. Motta G, Rojkaer R, Hasan AAK, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation. *Blood* 1998;91:516-528. [PubMed: 9427705]

4. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. *J Biol Chem* 2002;277:17962–17969. [PubMed: 11830581]
5. Gustafson EG, Schutsky D, Knight L, Schmaier AH. High molecular weight kininogen binds to unstimulated platelets. *J Clin Invest* 1986;78:310–318. [PubMed: 3722381]
6. Gustafson EJ, Schmaier AH, Wachtfogel YT, Kaufman N, Kucich U, Colman RW. Human neutrophils contain and bind high molecular weight kininogen. *J Clin Invest* 1989;84:28–25. [PubMed: 2738152]
7. Schmaier AH, Kuo A, Lundberg D, Murray SC, Cines DB. Expression of high molecular weight kininogen on human umbilical vein endothelial cells. *J Biol Chem* 1988;263:16327–16333. [PubMed: 2460446]
8. Reddigari SR, Shibayama Y, Brunnee T, Kaplan AP. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. *J Biol Chem* 1993;268:11982–11987. [PubMed: 8505323]
9. Shariat-Madar Z, Mahdi F, Schmaier AH. Factor XI assembly and activation on human umbilical vein endothelial cells in culture. *Thromb Haemost* 2001;85:544–551. [PubMed: 11307829]
10. Herwald H, Dedio J, Kellner R, Loos M, Muller-Esterl W. Isolation and characterization of the kininogen binding protein p33 from endothelial cells. *J Biol Chem* 1996;271:13040–13047. [PubMed: 8662673]
11. Joseph K, Ghebrehiwet B, Peerschke EIB, Reid KBM, Kaplan AP. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular “heads” of C1q (qC1qR). *Proc Natl Acad Sci* 1996;93:8552–8557. [PubMed: 8710908]
12. Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang j, Mazar A, McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. *J Clin Invest* 1997;100:1481–1487. [PubMed: 9294114]
13. Hasan AAK, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. *Proc Natl Acad Sci* 1998;95:3615–3620. [PubMed: 9520414]
14. Zhang J-C, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, Pang Y-P, McCrae KR. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. *Proc Natl Acad Sci* 2002;99:12224–12229. [PubMed: 12196635]
15. Mahdi F, Shariat-Madar Z, Figueroa CD, Schmaier AH. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin on endothelial cell membranes. *Blood* 2002;99:3585–3596. [PubMed: 11986212]
16. Renne T, Dedio J, David G, Muller-Esterl W. High molecular weight kininogen utilizes heparin sulfate proteoglycans for accumulation on endothelial cells. *J Biol Chem* 2000;275:33688–33695. [PubMed: 10843988]
17. Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. *J Immunol* 2005;175:3377–3385. [PubMed: 16116231]
18. Fernando LP, Fernando AN, Joseph K, Kaplan AP. Assessment of the role of heparan sulfate in high molecular weight kininogen binding to human umbilical vein endothelial cells. *J Thromb Haemost* 2003;1:2444–2449. [PubMed: 14629481]
19. Mahdi F, Shariat-Madar Z, Schmaier AH. The relative priority of prekallikrein and factors XI/XIa assembly on cultured endothelial cells. *J Biol Chem* 2003;278:43983–43990. [PubMed: 12944405]
20. Ho DH, Badellino K, Baglia FA, Sun MF, Zhao MM, Gailani D, Walsh PN. The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface. *J Biol Chem* 2000;275:25139–25145. [PubMed: 10823824]
21. Yun TH, Baglia FA, Myles T, Navaneetham D, Lopez JA, Walsh PN, Leung LL. Thrombin activation of factor XI on activates platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. *J Biol Chem* 2003;278:48112–48119. [PubMed: 12968031]
22. Mandle RJ, Colman RW, Kaplan AP. Identification of prekallikrein and high molecular weight kininogen complexes in plasma. *Proc Natl Acad Sci* 1976;73:4179–4183. [PubMed: 1069308]

23. Loza JP, Gurevich V, Johnstone M, Pannell R. Platelet-bound prekallikrein promotes prourokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. *Thromb Haemost* 1994;71:347–352. [PubMed: 8029800]
24. Motta G, Shariat-Madar Z, Mahdi F, Sampaio CAM, Schmaier AH. Assembly and activation of high molecular weight kininogen and prekallikrein on cell matrix. *Thromb Haemost* 2001;86:840–847. [PubMed: 11583317]
25. Lin Y, Harris RB, Yan W, Colman RW. High molecular weight kininogen peptides inhibit formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. *Blood* 1997;90:690–697. [PubMed: 9226169]
26. Rojkjaer R, Hasan AAK, Motta G, Schousboe I, Schmaier AH. Factor XII does not initiate prekallikrein activation on endothelial cells. *Thromb Haemost* 1998;80:74–81. [PubMed: 9684789]
27. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. *J Clin Invest* 2002;109:1057–1063. [PubMed: 11956243]
28. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. *Thromb Haemost* 2006;95:1003–1010. [PubMed: 16732380]
29. Yang HYT, Erdos EG, Chiang TS, Jenssen TA, Rogers JG. Characterization of an enzyme that inactivates angiotensin II (angiotensinase C). *Biochem Pharmacol* 1970;19:1201–1211.
30. Oyda CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdos EG. Purification and properties of prolylcarboxypeptidase (Angiotensinase C) from human kidney. *J Biol Chem* 1978;253:5927–5931. [PubMed: 28321]
31. Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. *Blood* 2004;103:4554–4561. [PubMed: 14996700]
32. Moreira CR, Schmaier AH, Mahdi F, da Motta G, Nader HB, Shariat-Madar Z. Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. *FEBS Letters* 2002;523:167–170. [PubMed: 12123826]
33. Kumamoto K, Stewart TA, Johnson AR, Erdos EG. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells. *J Clin Invest* 1981;67:210–215. [PubMed: 7451650]
34. Jackman HL, Tan F, Schraufnagel D, Dragovic T, Dezso B, Becker RP, Erdos EG. Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages. *Am J Respir Cell Mol Biol* 1995;13:196–204. [PubMed: 7626287]
35. Skarnes WC. Gene trapping methods for the identification and functional analysis of cell surface proteins in mice. *Method Enzymol* 2000;328:592–615.
36. Biederbick A, Rose S, Elsasser H-P. A human intracellular apyrase-like protein, LALP70, localizes to lysosomal/autophagic vacuoles. *J Cell Sci* 1999;112:2473–2484. [PubMed: 10393803]
37. McCarthy JJ, Meyer J, Moliterno DJ, Newby LK, Rogers WJ, Topol EJ. GenQuest multicenter study. Evidence for substantial effect modification by gender in a large scale genetic association study of the metabolic syndrome among coronary heart disease patients. *Hum Genet* 2003;114:87–98. [PubMed: 14557872]
38. Wang L, Feng Y, Zhang Y, Zhou H, Jiang S, Niu T, Wei LJ, Xu X, Xu X, Wang X. prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. *Am J Obstet Gynecol* 2006;195:162–171. [PubMed: 16681991]
39. Shariat-Madar Z, Rahimi E, Mahdi F, Schmaier AH. Over-expression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. *Am J Physiol Heart & Circ Physiol* 2005;289:H2697–H2703. [PubMed: 16113074]
40. Shariat-Madar Z, Mahdi F, Warnock M, Homeister JW, Srikanth S, Krijanovski Y, Murphey LJ, Jaffa AA, Schmaier AH. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. *Blood* 2006;108:192–199. [PubMed: 16514058]
41. Abadir PM, Periasamy A, Carey RM, Siragy HM. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. *Hypertension* 2006;48:316–322. [PubMed: 16754789]
42. Munoz CM, Leeb-Lundberg LM. Receptor-mediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradative pathways. *J Biol Chem* 1992;267:303–309. [PubMed: 1309739]

43. Schmaier AH. The kallikrein-kinin and renin angiotensin systems have a multilayered interaction. *Am J Physiol Regul Integr Comp Physiol* 2003;285:R1–R13. [PubMed: 12793984]
44. Groger M, Lebesgue D, Pruneau D, Relton J, Kim S-W, Nussberger J, Plesnila N. Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. *J Cerebral Blood Flow & Metabolism* 2005;25:978–989.
45. Xia C-F, Smith RS, Shen B, Yang Z-R, Borlongan CV, Chao L, Chao J. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. *Hypertension* 2006;47:752–761. [PubMed: 16534002]
46. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. *J Exp Med* 2005;280:28572–28580.
47. Colman RW. Is the plasma kallikrein-kinin system antithrombotic? *Blood* 2006;108:1.
48. Soria JM, Almasy L, Souto JC, Bacq D, Buil A, Faure A, Martinez-Marchan E, Mateo J, Borrell M, Stone W, Lathrop M, Fontcuberta J, Blangero J. A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease. *Am J Hum Genet* 2002;70:567–574. [PubMed: 11805911]
49. Zito F, Lowe GDO, Rumley A, McMahon AD, Humphries SE. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease in the WOSCOPS study. *Atherosclerosis* 2002;165:153–158. [PubMed: 12208481]
50. Colhoun HM, Zito F, Chan NN, Rubens MB, Fuller JH, Humphries SE. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. *Atherosclerosis* 2002;163:363–369. [PubMed: 12052484]
51. Roldan V, Corral J, Marin F, Pineda J, Vicente V, Gonzalez-Conejero R. Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. *Thromb Haemost* 2005;94:1294–1299. [PubMed: 16411408]
52. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. *Circulation* 2000;102:2816–2822. [PubMed: 11104738]
53. Grundt H, Nilsen DW, Hetland O, Valente E, Fagertun HE. Activation of factor XIIa2 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. *Am Heart J* 2004;147:260–266. [PubMed: 14760323]
54. Kleinschnitz C, Stoll G, Bendszuz M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T. Targeting coagulation factor XII provides protection from pathologic thrombosis in cerebral ischemia without interfering with hemostasis. *J Exp Med* 2006;203:513–518. [PubMed: 16533887]
55. Renne T, Nieswandt B, Gailani D. The intrinsic pathway of coagulation is essential for thrombus stability in mice. *Blood Cells Mol Dis* 2006;36:148–151. [PubMed: 16466946]
56. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. *Proc Natl Acad Sci USA* 2006;103:903–908. [PubMed: 16410357]
57. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Gunther A, Engelmann B, Preissner KT. *Proc Natl Acad Sci* 2007;104:6388–6393. [PubMed: 17405864]